Trials / Terminated
TerminatedNCT04426357
A Study to Evaluate the Effect of Renal Impairment on JNJ-64417184 and Its Two Minor Metabolites JNJ-68294291 and JNJ-65201526 in Adult Participants
A Single-dose, Open-label, Parallel-group Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of JNJ-64417184 and Its Two Minor Metabolites JNJ-68294291 and JNJ-65201526 in Adult Participants
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Janssen Pharmaceutica N.V., Belgium · Industry
- Sex
- All
- Age
- 18 Years – 79 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to evaluate the pharmacokinetics of JNJ-64417184, JNJ-68294291, and JNJ-65201526 after a single oral dose of JNJ-64417184 in adult participants with various degrees of impaired renal function (moderate \[optional\], severe renal impairment, and end stage renal disease (ESRD) not requiring hemodialysis) compared to participants with normal renal function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-64417184 | Participants will receive single oral (as film coated tablet) dose of JNJ-64417184 on Day 1. |
Timeline
- Start date
- 2020-07-03
- Primary completion
- 2020-11-12
- Completion
- 2020-11-12
- First posted
- 2020-06-11
- Last updated
- 2021-01-15
Locations
2 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT04426357. Inclusion in this directory is not an endorsement.